



Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting

JunB and JunD

Esmerina Tili¹, Jean-Jacques Michaille^{1,2,*}, Brett Adair¹, Hansjuerg Alder¹, Emeric Limagne², Cristian Taccioli¹, Manuela Ferracin³, Dominique Delmas², Norbert Latruffe² and Carlo M. Croce^{1,*}

¹Ohio State University, Department of Molecular Virology, Immunology and Medical Genetics, Biological Research Tower, 460 W. 12th Ave., Columbus, OH 43210, USA

²LBMN-INSERM U866, Université de Bourgogne, Faculté Gabriel, 6 Bd. Gabriel, 21000 DIJON, France

³Dipartimento di Medicina sperimentale e diagnostica, sez. Microbiologia, presso "Il Cubo", Università di Ferrara, via Via Fossato di Mortara, 70, 44100 Ferrara, Italia

*To whom correspondence should be addressed.

Tel: +33 380 39 62 11; Fax: +33 380 39 62 50; E-mail: jean-jacques.michaille@u-bourgogne.fr

Tel: +1 614 292 3063; Fax: +1 614 292 3558. E-mail: carlo.croce@osumc.edu

Running title: Resveratrol downregulates *miR-155* through *miR-663*

Key words: Inflammation; miR-155; monocytes; resveratrol; THP-1 cells

Abstract

An inflammatory component is present in the microenvironment of most neoplastic tissues, including those not causally related to an obvious inflammatory process. Several microRNAs, and especially *miR-155*, play an essential role in both the innate and adaptative immune response. Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural antioxidant with anti-inflammatory properties that is currently at the stage of pre-clinical studies for human cancer prevention. Here, we establish that, in human THP-1 monocytic cells as well as in human blood monocytes, resveratrol upregulates *miR-663*, a microRNA potentially targeting multiple genes implicated in the immune response. In THP-1 cells, *miR-663* decreases endogenous AP-1 activity and impairs its upregulation by LPS, at least in part by directly targeting *JunB* and *JunD* transcripts. We further establish that the downregulation of AP-1 activity by resveratrol is *miR-663* dependent, and that the effects of resveratrol on both AP-1 activity and JunB levels are dose-dependent. Finally, we show that resveratrol impairs the upregulation of *miR-155* by LPS in a *miR-663*-dependent manner. Given the role of *miR-155* in the innate immune response and the fact that it is upregulated in many cancers, our results suggest that manipulating *miR-663* levels may help to optimize the use of resveratrol as both an anti-inflammatory and anti-cancer agent against malignancies associated with high levels of *miR-155*.

Introduction

Epidemiological studies suggest that as many as 25 % of all cancers may be due to chronic inflammation (1-4). The connection between inflammation and cancer consists of an extrinsic pathway, driven by inflammatory conditions that increase cancer risk, and an intrinsic pathway, driven by genetic alterations that cause inflammation and neoplasia (2). Furthermore, inflammatory mediators released by cancer-related inflammation can induce genetic instability, leading to the accumulation of random genetic alterations in cancer cells (3). Beside resident cell types, such as fibroblasts and adipocytes, tumor microenvironment contains various inflammatory cell types infiltrating the tumor area in response to inflammatory stimuli, such as macrophages, neutrophils and mast cells (5-7). Tumor-associated macrophages (TAMs) are thought to play key roles in production of various growth factors, angiogenic factors, proteinases, chemokines and cytokines, through cross-talks with cancer cells and other tumor stromal cells (8-10). These factors in turn stimulate cell migration/motility, proliferation, survival, angiogenesis and metastasis, resulting in a dynamic environment that favors the progression of cancer, thus affecting the clinical outcome of malignant tumors (7). TAMs have thus been described as “obligate partners for tumor-cell migration, invasion and metastasis” (11). Namely, in a genetic model of breast cancer in macrophage-deficient mice, the tumors developed normally but were unable to form pulmonary metastases in the absence of macrophages (12). As tumor metastasis is responsible for approximately 90% of all cancer-related deaths, a better understanding of inflammation regulatory mechanisms may potentially allow to optimize the use of anti-cancer drugs that may target TAMs and lower tumor-specific inflammatory response (7).

MiRNAs (microRNAs) are short non-coding RNAs which regulate the translation and/or degradation of target messenger RNAs (13), and whose molecular malfunctions are associated with major pathologies such as cancers (14) or autoimmune diseases (15). Several miRNAs have been

implicated in the control of hematopoietic lineage differentiation (16-18). Among them, *miR-155* has been implicated in the regulation of myelopoiesis and erythropoiesis, Th1 differentiation, B cell maturation, IgG1 production, somatic hypermutations, gene conversion, class switch recombination, B and T cell homeostasis as well as in the regulation of the innate immune response (19, and references therein). Thus, *miR-155* levels increase following LPS treatment of THP-1 cells or Raw-264 macrophages, and *miR-155* transgenic mice show enhanced sensibility to LPS-induced endotoxin shock (20-22). In contrast, *miR-155*-knockout mice are unable to mount a proper T-cell or B-cell immune response (23). On the other hand, the immune response is limited by the upregulation of anti-inflammatory miRNAs such as *miR-146a* and *miR-146b*, which target IRAK-1 and TRAF-6 (20,24). Importantly, several reports have recently established a direct link between elevated levels of *miR-155* expression and the formation and development of tumors such as leukemias and breast, lung or gastric cancers (19). Elevated *miR-155* levels are linked with enhanced cell proliferation (16,17), transgenic mice with B cells overexpressing *miR-155* develop B-cell leukemia (25), and a sustained expression of *miR-155* in hematopoietic stem cells causes a myeloproliferative disorder (26).

Resveratrol (trans-3,4',5-trihydroxystilbene) is a dietary polyphenolic, non-flavonoid antioxidant derived from grapes, berries, peanuts, and other plant sources. Resveratrol has various health benefits, such as cardiovascular and cancer preventive properties (27-29), and it is currently at the stage of pre-clinical studies for human cancer prevention (29,30). Some of resveratrol protective activities are associated with the downregulation of the inflammatory response through inhibitory effects on transcription factors like NF- κ B or AP-1 (Activator Protein-1) components c-Jun and c-Fos, including the inhibition of the release of pro-inflammatory mediators such as reactive oxygen, nitrogen species and prostaglandin E2, or of enzymes implicated in their synthesis

(27,31,32). In adipocytes, resveratrol inhibits the production of the TNF-induced MCP-1, which has been implicated in chronic low grade inflammation, a key feature of obesity type 2 diabetes (33).

To date, it is not known if the anti-tumor and anti-inflammatory effects of resveratrol may rely on the modulation of expression of either pro-inflammatory or anti-inflammatory miRNAs. To address this question, we pretreated human THP-1 monocytes with resveratrol before challenging them with LPS. We show that resveratrol impairs the upregulation of oncogenic pro-inflammatory *miR-155* by LPS, at least in part through the upregulation of *miR-663*, a miRNA targeting *JunB* and *JunD* transcripts.

Materials and methods

Microarray analyses

RNAs extracted with TRIzol (Invitrogen) were subsequently subjected to DNase digestion (Turbo-DNase-Ambion). Affymetrix and miRNA microarray analyses were done at the Ohio State University microarray facility.

Cell culture, treatment and transfection

THP-1 cells were electroporated using the AMAXA kit (Lonza). LPS stimulation was done with *Salmonella enteritidis*-derived LPS (100 ng/ml, Sigma). Whenever needed, cells were pretreated 14 hours with either the vehicle (ethanol) or resveratrol 50 μ M.

Isolation and treatment of human blood monocytes

Human peripheral blood monocytes were obtained from healthy donors. Monocytes were enriched using a Monocyte Isolation Kit with uMACS Separator according to the manufacturer's instructions (Miltenyi Biotec). They were subsequently grown for 24 hours in RPMI 1640 medium with glutamax-I (Lonza) supplemented with 10% fetal bovine serum (Lonza) in standard

conditions, and exposed to 100 ng/mL CSF-1. Cell viability was assessed using Trypan blue. Monocytes were then treated for 14 hours with either the vehicle or resveratrol 30 μ M before RNA extraction.

RNase-protection assays

Assays were performed using the *mirVana* miRNA Probe Construction Kit and the *mirVana* miRNA Detection Kit from Ambion. RNAs were incubated overnight at 46 °C in the presence of 8×10^4 cpm of antisense RNA probe and then digested for 40 minutes at 37 °C using a 1/50 dilution of the provided RNase A/RNase T1 solution.

Preparation of clones and mutagenesis

The 3'-UTRs of *JunB* and *JunD* were cloned by PCR from HEK-293 cells genomic DNA and then inserted downstream of the *Luciferase* gene in the *XbaI* site of the *pGL3-Control* vector (Promega). *MiR-663* target sites were mutated using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). Sequences of the mutated *miR-663* target sites in *JunB* and *JunD* 3'-UTRs are given in Supplementary Table II.

Luciferase assays

Cells (1×10^6) in 6-well plates were transfected with 0.4 μ g of DNA (Promega *pGL3-Control* vector or derived constructs), *pre-miR-663* or *663-I* (50 nM final, Ambion) and 20 ng of *Renilla* Luciferase control vector (*pRL-TK* from Promega). Assays were performed 48 hours after transfection using the Dual Luciferase Reporter Assay System (Promega). *Firefly* luciferase activity was normalized to *Renilla* luciferase activity. The pre-miR Precursor Molecule-Negative Control #1 (Ambion) was used as a pre-miR control. AP-1 activity was measured using the Signal AP-1 Luciferase Reporter Assay Kit (Super Array Bioscience Corporation).

Quantitative Real-time PCR (qRT-PCR)

MiR-155 qRT-PCRs were performed using TaqMan MicroRNA Assays (Applied Biosystems). Values were normalized using either *RNU-44* or *RNU-48*. Real-time PCRs were run in triplicates from three different cDNAs.

Western blots

Anti-JunB, anti- α -Tubulin and anti-GAPDH antibodies were from Cell Signaling Technology. Anti-JunD was from Abcam. Anti-cMaf was from Santa Cruz. The relative intensities of the bands of interest, preably normalized to GAPDH or α Tubulin, are given under each panel in percent of the respective control sample.

Results

Resveratrol upregulates miR-663

Affymetrix micro-arrays showed that resveratrol modulated the levels of a number of transcripts in THP-1 cells, expectedly upregulating those coding for anti-proliferation factors while downregulating those coding for pro-proliferation factors (MIAME E-TABM-782). The most significant change was a roughly 20 times upregulation of *LOC284801* transcripts, which contain the sequence of *pre-miR-663* and thus represent *miR-663* primary transcripts. *In silico* analysis using TargetScan (<http://www.targetscan.org/>) showed that *miR-663* potentially targets transcripts of several genes implicated in the immune response (Supplementary Table I), and especially *JunB*, *JunD* and *FosB*, which encode AP-1 factors known to activate many cytokine genes in partnership with NFAT factors (34).

Due to *miR-663* base composition (20 CG/22 nt), no TaqMan probe is presently available for qRT-PCR. However, miRNA micro-arrays also showed that resveratrol upregulates *miR-663* by

roughly 75 % (MIAME E-TABM-780). This was further confirmed by RNase-protection assays (Figure 1). Furthermore, miRNA micro-arrays (to be submitted upon acceptance of the manuscript) also showed that a lower dose (30 μ M) of resveratrol still induced similar changes in miRNA populations from human blood monocytes, with the levels of *miR-663* increasing roughly by 30 %.

MiR-663 targets AP-1 activity as well as JunB and JunD transcripts

In the presence of LPS, both the surge of AP-1 activity and the upregulation of JunB, an AP-1 factor whose transcript levels peak within the first hour of LPS challenge (35) were impaired by *miR-663* overexpression in THP-1 cells (Figure 2A and 2B, respectively). This indicates that transcripts encoding JunB and possibly other AP-1 factors upregulated during the mounting of the inflammatory response to LPS are targeted, directly or indirectly, by *miR-663*. In addition, a *miR-663* inhibitory RNA (*663-I*) increased both AP-1 activity and JunB levels in non-challenged THP-1 cells, suggesting that *miR-663* normally works to impair any sudden surge of AP-1 activity or JunB levels in resting cells (Figure 2A and 2B). Finally, luciferase assays using constructs containing *JunB* 3'-untranslated region (UTR) with wild type or mutated *miR-663* target sites provided strong evidence that *miR-663* targets *JunB* 3'-UTR directly (Figure 2C). Furthermore, the effects of both *miR-663* and *663-I* on JunD levels and those of *miR-663* on the expression of a construct containing the 3'-UTR of *JunD*, a gene encoding another AP-1 factor, were quite similar (Supplementary Figure 1A and 1B, respectively). Together, these results establish *miR-663* as a new regulator of JunB and JunD levels, and more generally of AP-1 activity.

Of note, *663-I* failed to further increase AP-1 activity or JunB levels following LPS challenge (Figure 2A and 2B, respectively). This suggested that either AP-1 activity and JunB already reached their maximum possible levels under LPS challenge in the presence of control

RNA or that the innate immune response might reduce *miR-663* endogenous levels. Indeed, the levels of both *miR-663* and *pre-miR-663* decreased roughly 25 % within 30 minutes of LPS challenge (Supplementary Figure 2). Of note, the levels of *pri-miR-663* remained unchanged, suggesting that LPS signaling may decrease the processing of *pri-miR-663* by Drosha without impacting the transcription of the *miR-663* host gene.

Resveratrol decreases AP-1 activity through miR-663

As resveratrol decreases the levels and binding activities of AP-1 factors c-Jun and c-Fos (32), whose transcripts do not contain any *miR-663* target site, we then checked if it may also control AP-1 activity through the upregulation of *miR-663*. As expected, resveratrol decreased AP-1 activity in non-challenged THP-1 cells (Figure 3A). This effect was dose-dependent (Supplementary Figure 3A). Resveratrol also proved capable to decrease JunB levels in unchallenged cells in a dose-dependent manner (Supplementary Figure 3B). Furthermore, resveratrol still decreased AP-1 activity following LPS challenge (Figure 3A). Also, in agreement with the results of Figure 2A, *663-I* sharply increased AP-1 activity in untreated non-challenged cells, but not following LPS treatment (Figure 3A). Importantly, *663-I* significantly impaired the downregulating effects of resveratrol on AP-1 activity following LPS challenge, indicating that JunB, JunD and/or possibly FosB levels decreased as a consequence of the upregulation of *miR-663* by resveratrol. Accordingly, resveratrol impaired JunB upregulation following LPS-challenge (Figure 3B). *663-I* however did not significantly impair the downregulation of AP-1 activity by resveratrol in non-challenged cells (Figure 3A), suggesting that the effects of resveratrol in resting cells are mainly directed on AP-1 components not targeted by *miR-663*, presumably c-Jun and c-Fos. Thus, the upregulation of *miR-663* may allow resveratrol to change the composition, and most probably the activity, of AP-1 dimers following LPS challenge.

We then checked if the downregulation of JunB by resveratrol was *miR-663*-dependent. As shown previously for AP-1 activity (Figure 3A), *663-I* increased sharply JunB levels in untreated non-challenged THP-1 cells but proved incapable of increasing JunB levels further following LPS challenge of untreated cells (Figure 3C). Of note, when cells had been preably transfected, the upregulation of JunB by LPS was roughly three fold less (compare panels B and C of Figure 3). This suggests that transfection might by itself elicit some kind of response, with the result of decreasing the sensibility and thus the further response of THP-1 cells to LPS. Finally, *663-I* seemingly increased slightly the capability of resveratrol to bring down JunB levels following LPS challenge. This counter-intuitive result was not due to a lack of targeting of *JunB* transcripts by *miR-663*. Namely, as shown by luciferase assays, resveratrol as expected decreased the expression of *Luc-JunB* (Figure 3D) and *Luc-JunD* (Supplementary Figure 1C) constructs in a *miR-663*-dependent manner, thus giving a further evidence that it upregulates *miR-663*. It may be that *663-I* could also impair the targeting of transcripts encoding some unidentified repressor of *JunB* by *miR-663*. Nevertheless, all together, these results indicate that resveratrol can downregulate AP-1 activity by both *miR-663*-dependent and *miR-663*-independent mechanisms.

Resveratrol impairs the upregulation of oncogenic pro-inflammatory miR-155 by LPS at least partly through miR-663

The upregulation of *miR-155* is the hallmark of inflammatory response following LPS treatment of THP-1 cells (21) or Raw-264 macrophages (22). In B cells, AP-1 factors such as JunB and FosB transcriptionally activate *BIC*, whose transcripts represent *miR-155* primary RNAs (36). Given their effects on AP-1 activity, *miR-663* and resveratrol would thus be expected to impair the upregulation of *miR-155* by LPS. Indeed, transfecting THP-1 cells with *pre-miR-663* limited *miR-155* upregulation following LPS challenge (Figure 4A). In contrast, *663-I* remained without

obvious effects, which was probably due to the downregulation of *miR-663* by LPS (Supplementary Figure 2) and also possibly to the fact that the maximum possible levels of *miR-155* were already reached in LPS-challenged control cells. Accordingly, resveratrol impaired the LPS-induced upregulation of *miR-155* (Figure 4B), and consequently suppressed the downregulation of c-Maf, a validated target of *miR-155* (23) (Figure 4C). In addition, *663-I* slightly but significantly limited the capability of resveratrol to downregulate *miR-155* (Figure 4D). Thus, some of the effects of resveratrol on oncogenic pro-inflammatory *miR-155*, and therefore also presumably some of its anti-tumor effects, are due to its upregulation of *miR-663*.

Discussion

Our study provides the very first data concerning the effects of resveratrol on miRNAs and its ability to both upregulate *miR-663* and downregulate oncogenic pro-inflammatory *miR-155*. It provides strong support that: [i] *miR-663* targets *JunB* and *JunD* transcripts, consequently decreasing JunB and JunD levels as well as AP-1 activity; [ii] *miR-663* also potentially targets transcripts encoding several other factors needed for the innate immune response; [iii] the downregulation of AP-1 activity by resveratrol is *miR-663*-dependent; [iv] resveratrol impairs the upregulation of *miR-155* by LPS at least in part by upregulating the anti-inflammatory *miR-663*.

Transcripts from the *LOC284801* locus on chromosome 20, which represent *miR-663* primary RNAs, showed the highest statistically significant level change following resveratrol treatment of THP-1 cells, as deduced from Affymetrix microarray analysis. Although no probe is presently available to follow *miR-663* accumulation by qRT-PCR, due to its more than 92 % CG content, miRNA microarrays, RNase-protection and luciferase assays provided independent confirmations of the upregulation of mature *miR-663* by resveratrol. As it is the case for many other miRNAs, *miR-663* upregulation was not proportional to that of its primary transcripts, which

probably reflects post-transcriptional regulations.

Our results confirm the downregulation of AP-1 activity by resveratrol. However, while previous reports mainly focused on resveratrol effects on c-Jun and c-Fos, our results show that resveratrol can specifically target JunB and JunD by increasing *miR-663* levels, and suggest that the same miRNA could also target *FosB* transcripts. This is an important result, for AP-1 factors include c-Jun, JunB, JunD, FosB, Fra-1 and Fra-2, as well as Jun dimerization partners JDP1 and JDP2 or the closely related ATF2, LRF1/ATF3 and B-ATF, so that potentially about 18 different dimeric combinations may be formed. Thus, the capability of resveratrol to upregulate *miR-663* to specifically target a subset of AP-1 dimers might have profound effects on the levels of expression of promoters to whom different AP-1 factors can compete to bind to. Due to the many roles of AP-1 factors both in inflammation (37) and cancer (38,39), the specific targeting of genes encoding a subset of AP-1 factors, by changing the composition of AP-1 dimers on key promoters, may possibly explain some of resveratrol anti-inflammatory and anti-cancer properties. However, while *663-I* increased luciferase activity produced from *Luc-JunB* and *Luc-JunD* constructs in the presence of resveratrol, it failed to impair the downregulation of JunB by resveratrol, indicating that *miR-663* independent effects were also taking place. This was probably due to the fact that resveratrol downregulates the pro-inflammatory NF- κ B activity (32), which is needed for *JunB* activation (40). Also, *663-I* failed to increase JunB levels following LPS challenge. This is probably due in part to the fact that LPS challenge decreased *miR-663* levels. It is also possible that JunB might have already reached its maximum possible levels under LPS challenge in control experiment, that LPS may limit *miR-663* access to *JunB* transcripts, or that *miR-663* might target transcripts encoding an unidentified repressor of *JunB*.

Importantly, *miR-663* also potentially targets transcripts encoding factors playing a role not

only in TLR signaling and the innate immune response to LPS, but also in granulopoiesis, monopoiesis, $\text{INF}\gamma$ signaling, Th17 lymphocytes differentiation or TCR signaling. The functions of *miR-663* are thus probably not restricted to the monocyte/macrophage lineage.

Our results also show that *miR-663* impairs the upregulation of *miR-155* by LPS. This effect may be due to the targeting of JunB or FosB, which have been shown to transcriptionally activate *BIC*, namely *miR-155* host gene (36). Also, *miR-663* potentially targets *KSRP* transcripts, which encode a RNA binding protein implicated in the LPS-induced *miR-155* maturation from its primary transcripts *BIC* (41). Given the facts [i] that AP-1 factors participate to the activation of many pro-inflammatory cytokine genes in partnership with NFAT factors (37) and are implicated in the upregulation of *miR-155* by LPS, [ii] that *miR-155* upregulation is a hallmark of innate immune response (21,22), and [iii] that *miR-663* levels decreased at the very beginning of LPS challenge (this manuscript), *miR-663* is likely to work along with *miR-146a* and *miR-146b* to control the intensity of the innate immune response. Furthermore, beside its roles in myeloid differentiation and innate response, *miR-155* has many other functions in the immune system, such as the regulation of myelopoiesis and erythropoiesis, Th1 differentiation, B cell maturation, IgG1 production, somatic hypermutations, gene conversion, class switch recombination, or B and T cell homeostasis (19). It will thus be very interesting to determine if *miR-663* can also modulate *miR-155* levels and functions in these different cell types.

Finally, the fact that resveratrol decreases both AP-1 activity and *miR-155* levels at least in part through the upregulation of *miR-663* could be critical in optimizing the use of resveratrol as an anti-inflammatory but also as an anti-tumor agent. Namely, several reports have recently established a direct link between elevated levels of *miR-155* expression and the formation and development of tumors such as leukemias and breast, lung or gastric cancers (19). Elevated *miR-*

155 levels are linked with enhanced cell proliferation (16,17), transgenic mice with B cells overexpressing *miR-155* develop B-cell leukemia (25), and a sustained expression of *miR-155* in hematopoietic stem cells causes a myeloproliferative disorder (26). These transgenic mice also showed that one of the many effects of *miR-155* is the enhancement of cell proliferation. Of note, resveratrol impaired the upregulation of cyclins B1 and D3 by LPS (results not shown). This suggests that, beside opposing the proliferative effects of AP-1 factors, resveratrol may also oppose the proliferative activity of *miR-155* through the upregulation of *miR-663*. Importantly, *miR-663* was found to be downregulated in hormone refractory prostate cancer cells, along with *miR-146a* and *miR-146b* (42). Unfortunately, *miR-663* is not present in mouse genome, thus impairing direct experimentation using knock-out animals.

Nevertheless, while resveratrol anticarcinogenic potential has been linked with data primarily from human cell culture systems, evidence that resveratrol can inhibit carcinogenesis in several organ sites emerged from results of cancer prevention and therapy studies in laboratory animal models (29). However, previous results have shown that, at least when it comes to the immune system, the expression and thus potentially the function of miRNAs cannot be directly transposed from one species to another one. For example, the upregulation of anti-inflammatory *miR-146a* and *miR-146b* during the innate immune response has been observed only in human cell lines, such as THP-1 (20) or A549 cells (24), but not in mouse cell lines or in mouse spleen macrophage (22,43). As *miR-663* is found only in primates, our results come as a warning that studies in animal may not always allow to predict accurately the molecular effects of resveratrol in human.

Supplementary material

Supplementary Figures 1, 2, 3 and 4 as well as Supplementary Tables I and II can be found at <http://carcin.oxfordjournals.org/>

Funding

This work was funded by the Comprehensive Cancer Center of the Ohio State University, the Ligue contre le Cancer, the BIVB and the Conseil Régional de Bourgogne.

Conflict of Interest Statement: None declared.

References

1. Hussain,S.P. and Harris,C.C. (2007) Inflammation and cancer: an ancient link with novel potential. *Int. J. Cancer*, **121**, 2373-2380.
2. Montovani,A., Allavena,P., Sica,A. and Balkwill,F. (2008) Cancer-related inflammation. *Nature*, **454**, 436-444.
3. Colotta,F., Allavena,P., Sica,A., Garlanda,C. and Motovani,A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*, **30**, 1073-1082.
4. Schetter,A.J., Heegard,N.H.H. and Harris,C.C. (2009) Inflammation and Cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. *Carcinogenesis*, doi:10.1093/carcin/bgp272.
5. Balkwill,F. and Mantovani,A. (2001) Inflammation and cancer: back to Virchow? *Lancet*, **357**, 539-545.
6. Coussens,L.M. and Werb,Z. (2002). Inflammation and cancer. *Nature*, **420**, 860-867.

7. Ono,M. (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. *Cancer Sci.*, **99**, 1501-1506.
8. Pollard,J.W. (2004). Tumor-educated macrophages promote tumor progression and metastasis. *Nat Rev Cancer*, **4**, 71–8.
9. Yoshimura,A. (2006) Signal transduction of inflammatory cytokines and tumor development. *Cancer Sci.*, **97**, 439-47.
10. Sica,A. and Bronte V. (2007) Altered macrophage differentiation and immune dysfunction: tumor development. *J. Clin. Invest.*, **117**, 1155-1165.
11. Condeelis,J. and Pollard,J.W. (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell*, **124**, 263-266.
12. Lin,E.Y., Nguyen,A.V., Russell,R.G. and Pollard,J.W. (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J. Exp. Med.*, **193**, 727-740.
13. Ambros,V. (2004) The functions of animal miRNAs. *Nature*, **431**, 350-355.
14. Calin,G.A. and Croce,C.M. (2006) MiRNA signatures in human cancers. *Nat. Rev. Cancer*, **6**, 857–866.
15. Tili,E., Michaille,J.-J., Costinean,S. and Croce,C.M. (2008b) MicroRNAs, the immune system and rheumatic disease. *Nat. Clin. Pract. Rheumatol.*, **10**, 534-541.
16. Lindsay,M.A. (2008) microRNAs and the immune response. *Trends Immunol.* **29**, 243-351.
17. Tili,E., Michaille,J.-J. and Calin,G.A. (2008a) Expression and function of micro-RNAs in immune cells during normal or disease state. *Int. J. Med. Sci.*, **5**, 73-79.

18. Tsitsiou,E., Lindsay,M.A. (2009) microRNAs and the immune response. *Curr. Opin. Pharmacol.*, **9**, 514–520.
19. Tili,E., Croce,C.M. and Michaille,J.-J. (2009) *miR155*: On the crosstalk between inflammation and cancer. *Int. Rev. Immunol.*, **28**, 264-284.
20. Taganov,K.D., Boldin,M.P., Chang,K.J. and Baltimore,D. (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc. Natl. Acad. Sci. U.S.A.*, **103**, 12481-12486.
21. O’Connell,R.M., Taganov,K.D., Boldin,M.P., Cheng,G. and Baltimore,D. (2007) MicroRNA-155 is induced during the macrophage inflammatory response. *Proc. Natl. Acad. Sci. U.S.A.*, **104**, 1604-1609.
22. Tili,E., Michaille,J.-J., Cimino,A., Costinean,S., Dumitru,D.C., Adair,B., Fabbri,M., Alder,H., Liu,C.-G., Calin,G.A. and Croce,C.M. (2007) Modulation of miR-155 and miR-125b levels following LPS/TNF- α stimulation, and their possible roles in regulating the response to endotoxin shock. *J. Immunol.*, **179**, 5082-5089.
23. Rodriguez,A., Vigorito,E., Clare,S., Warren,M.V., Couttet,P., Soond,D.R., van Dongen,S., Grocock,R.J., Das,P.P., Miska,E.A., Vetrie,D., Okkenhaug,K., Enright,A. J., Dougan,G., Turner,M. and Bradley,A. (2007) Requirement of *bic/microRNA-155* for normal immune function. *Science*, **316**, 608-611.
24. Perry,M.M., Moschos,S.M., Williams,A.E., Shepherd,N.J., Larner-Svensson,H.M. and Lindsay,M.A. (2008) Rapid changes in microRNA-146a expression negatively regulate the IL-1 β -induced inflammatory response in human lung alveolar epithelium cells. *J. Immunol.*, **180**, 5689-5698.

25. Costinean,S., Zanesi,N., Pekarski,Y., Tili,E., Volinia,S., Heerema,N. and Croce,C.M. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in *E(mu)-miR155* transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.*, **103**, 7024-7029.
26. O'Connell,R.M., Rao,D.S., Chaudhuri,A.A., Boldin,M.P., Taganov,K.D., Nicoll,J., Paquette,R.L. and Baltimore,D. (2008) Sustained expression of microRNA-155 in hematopoietic stem cell causes a myeloproliferative disorder. *J. Exp. Med.*, **205**, 585-594.
27. Csiszar,A., Smith,K., Labinskyy,N., Orosz,Z., Rivera,A. and Ungvari,Z. (2006) Resveratrol attenuates TNF α -induced activation of coronary arterial endothelial cells: role of NF- κ B inhibition. *Am. J. Physiol. Heart Circ. Physiol.*, **291**, H1694-H1699.
28. Shankar,S., Singh,G. and Srivastava,R.K. (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. *Front. Biosci.*, **12**, 4839-4854.
29. Bishayee,A. (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. *Cancer Prev. Res.*, **2**, 409-418.
30. Athar,M., Back,J.H., Tang,X., Kim,K.H., Kopelovich,L., Bickers,D.R. and Kim,A.L. (2007) Resveratrol: a review of preclinical studies for human cancer prevention. *Toxicol. Appl. Pharmacol.*, **224**, 274-283.
31. Leiro,J., Alvarez,E., Arranz,J.A., Laguna,R., Uriarte,E. and Orallo,F. (2004) Effects of *cis*-resveratrol on inflammatory murine macrophages: antioxidant activity and downregulation of inflammatory genes. *J. Leukoc. Biol.*, **75**, 1156-1165.
32. Das,S. and Das,D.K. (2007) Anti-inflammatory responses of resveratrol. *Inflamm. Allergy Drug Targets*, **6**, 168-173.

33. Zhu,J., Yong,W., Wu,X., Yu,Y., Iv,J., Liu,C., Mao,X., Zhu,Y., Xu,K., Han,X. and Liu,C. (2008) Anti-inflammatory effect of resveratrol on TNF- α -induced MCP-1 expression in adipocytes. *Bioch. Bioph. Res. Commun.*, **369**, 471-477.
34. Macian,F., Lopez-Rodriguez,C. and Rao,A. (2001) Partners in transcription: NFAT and AP-1. *Oncogene*, **20**, 2476-2489.
35. Fujihira,M., Muroi,M., Muroi,Y., Ito,N. and Suzuki,T. (1993) Mechanism of lipopolysaccharide-triggered *JunB* activation in a mouse macrophage-like cell line (J774). *J. Biol. Chem.*, **268**, 14896-14905.
36. Yin,Q., Wang,X., McBride,J., Fewell,C. and Flemington,E. (2008) B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. *J. Biol. Chem.*, **283**, 2654-2662.
37. Blank,V. and Andrews,N.C. (1997) The Maf transcription factors: regulators of differentiation. *Trends Biochem. Sci.*, **22**, 437-441.
38. Ozanne,B.W., Spence,H.J., McGarry,L.C. and Hennigan,R.F. (2007) Transcription factors control invasion: AP-1 the first among equals. *Oncogene*, **26**, 1-10.
39. Verde,P., Casalino,L., Talotta,F., Yaniv,M. and Weitzman,J.B. (2007) Deciphering AP-1 function in tumorigenesis: Fra-ternizing on target promoters. *Cell Cycle*, **6**, 2632-2639.
40. Krappmann,D., Wegener,E., Sunami,Y., Esen,M., Thiel,A., Mordmuller,B. and Scheidereit,C. (2004) The I κ B kinase complex and NF- κ B act as master regulators of lipopolycaccharide-induced gene expression and control subordinate activation of AP-1. *Mol. Cell. Biol.*, **24**, 6488-6500.

41. Ruggiero,T., Trabucchi,M., De Santa,F., Zupo,S., Harfe,B.D., McManus,M.T., Rosenfeld,M.G., Briata;P. and Gherzi,R. (2009) LPS-induces KH-type splicing regulatory protein-dependent processing of miRNA-155 precursors in macrophages. *FASEB J.*, **23**, 2898-2908.
42. Lin,S.-L., Chiang,A., Chang,D. and Ying,S.-Y. (2008) Loss of miR-146a function in hormone-refractory prostate cancer. *RNA*, **14**, 417-424.
43. Androulidaki,A., Iliopoulos,D., Arranz,A., Doxaki,C., Schworer,S., Zacharioudaki,V., Margioris,A.N., Tsihliis,P.N. and Tsatsanis,C. (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. *Immunity*, **31**, 220-231.

Legends to figures

Fig. 1. Resveratrol increases the levels of both *miR-663* and *LO284801* transcripts.

Total RNAs (0.6 μ g) extracted from THP-1 cells treated 14 hours with the vehicle (V) or resveratrol (R) were hybridized with a radiolabelled RNA antisense probe (P1, P2, P3 or U6) in the presence of 4.4 μ g of yeast tRNA. The schematic structure of the *LO284801* locus, whose transcripts represent *miR-663* primary transcripts, is presented on the unscaled top drawing. Open and filled boxes represent *miR-663* precursor (*pre-miR-663*) and mature *miR-663*, respectively. P1 is located 1,308 bp upstream of *pre-miR-663* and corresponds to one of the Affymetrix probes. P2 is located 151 bp upstream of *pre-miR-663*. *Pre-miR-663* and *miR-663* respectively generate 40 and 22 nt-long protected fragments from P3, which corresponds to one of the miRNA microarrays probes. The relative intensity of the signal following resveratrol treatment is given between parentheses in percent of the vehicle sample, calculated using *U6snRNA* as an internal control. The efficiency of RNase digestion was assessed in parallel (two left lanes). C-, no RNase (15 fold dilution); C+, RNase; Nd, non digested; Pr, protected fragment.

Fig. 2. *MiR-663* decreases AP-1 activity and targets *JunB*.

A. AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA, *pre-miR-663* (663) or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 hours). Values represent the mean \pm standard deviation (n = 3). * and **, Significantly different from the corresponding mock-challenged sample, *, $P < 0.001$, **, $P < 0.0005$. o, Significantly different from LPS-challenged Control, $P < 0.0008$. #, Significantly different from mock-challenged Control, $P < 0.0001$.

B. The levels of JunB in THP-1 cells transfected with either a pre-miR Control, *pre-miR-663* or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 hours), were determined by Western Blotting.

C. Effects of *pre-miR-663* on *Luc-JunB* constructs, both in sense and antisense orientation. Sequences of the two mutated *miR-663* target sites in *JunB* sense constructs (M663) are given in Supplementary Table II. Values represent the mean \pm standard deviation (n = 4). * and **, Significantly different from Pre-miR-Control, *, $P < 0.001$, **, $P < 0.0001$.

Fig. 3. Resveratrol decreases AP-1 activity in a *miR-663*-dependent manner.

A. AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 hours, and subsequently challenged or not with LPS for 6 hours. Values represent the mean \pm standard deviation (n = 3). *, Significantly different from the corresponding mock-challenged sample, $P < 0.005$. o and oo, Significantly different from the corresponding Vehicle-treated sample, o, $P < 0.03$, oo, $P < 0.001$. #, Significantly different from the LPS-challenged Resveratrol-treated Control, $P < 0.005$. ##, Significantly different from the mock-challenged Vehicle-treated Control, $P < 0.0005$.

B. The effects of a 14 hours resveratrol pretreatment on the accumulation of JunB following LPS challenge were determined by Western blotting.

C. The levels of JunB in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 hours and subsequently challenged or not with LPS for 6 hours, were determined by Western blotting.

D. Effects of a 14 hours resveratrol treatment on the expression of wild-type (WT) or mutated (M663) *Luc-JunB* constructs. Values represent the mean \pm standard deviation (n = 4). * and **, Significantly different from the corresponding WT / Control, *, $P < 0.007$, **, $P < 0.0009$.

Fig. 4. Resveratrol opposes the upregulation of *miR-155* at least in part by upregulating *miR-663*.

A. The relative expression of *miR-155* in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I) and subsequently challenged or not with LPS for 6 hours were determined by qRT-PCR. Values represent the mean \pm standard deviation (n = 3). *, Significantly different from the corresponding mock-challenged sample, $P < 0.06$. o, Significantly different from LPS-challenged Control, $P < 0.005$.

B. Time-course of *miR-155* expression in LPS-challenged THP-1 cells, pretreated or not with resveratrol, as determined by qRT-PCR. Values represent the mean \pm standard deviation (n = 3).

C. The levels of c-Maf in THP-1 cells pretreated with vehicle or resveratrol for 14 hours and subsequently challenged or not with LPS for 6 hours were determined by Western blotting.

D. The relative expression of *miR-155* in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I) and then pretreated with vehicle or resveratrol for 14 hours and subsequently challenged or not with LPS for 6 hours were determined by qRT-PCR. Values represent the mean \pm standard deviation (n = 3). * and **, Significantly different from the corresponding mock-challenged sample, *, $P < 0.014$, **, $P < 0.004$. o and oo, Significantly different from LPS-challenged vehicle-treated Control, o, $P < 0.02$, oo, $P < 0.0001$. #, Significantly different from LPS-challenged resveratrol-treated Control, $P < 0.05$.




Fig. 1. Resveratrol increases the levels of both miR-663 and LO284801 transcripts. Total RNAs (0.6 μ g) extracted from THP-1 cells treated 14 h with the vehicle (V) or resveratrol (R) were hybridized with a radiolabelled RNA antisense probe (P1, P2, P3 or U6) in the presence of 4.4 μ g of yeast transfer RNA. The schematic structure of the LOC284801 locus, whose transcripts represent miR-663 primary transcripts, is presented on the unscaled top drawing. Open and filled boxes represent miR-663 precursor (pre-miR-663) and mature miR-663, respectively. P1 is located 1308 bp upstream of pre-miR-663 and corresponds to one of the Affymetrix probes. P2 is located 151 bp upstream of pre-miR-663. Pre-miR-663 and miR-663, respectively, generate 40 and 22 nt long protected fragments from P3, which corresponds to one of the miRNA microarrays probes. The relative intensity of the signal following resveratrol treatment is given between parentheses in percent of the vehicle sample, calculated using U6snRNA as an internal control. The efficiency of RNase digestion was assessed in parallel (two left lanes). C-, no RNase (15-fold dilution); C+, RNase; Nd, non-digested; Pr, protected fragment.




Fig. 2. *miR-663* decreases AP-1 activity and targets *JunB*. (A) AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA, *pre-miR-663* (663) or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 h). Values represent the mean \pm standard deviation ($n = 3$). * and **, significantly different from the corresponding mock-challenged sample, * $P < 0.001$ and ** $P < 0.0005$. o, significantly different from LPS-challenged Control, $P < 0.0001$. #, significantly different from mock-challenged Control, $P < 0.0008$. (B) The levels of *JunB* in THP-1 cells transfected with either a premiR Control, *pre-miR-663* or a *miR-663* inhibitor RNA (663-I), with or without LPS challenge (6 h), were determined by western blotting. (C) Effects of *premiR-663* on *Luc-JunB* constructs, both in sense and antisense orientation. Sequences of the two mutated *miR-663* target sites in *JunB* sense constructs (M663) are given in supplementary Table II, available at *Carcinogenesis* Online. Values represent the mean \pm standard deviation ($n = 4$). * and **, significantly different from Pre-miR-Control, * $P < 0.001$ and ** $P < 0.0001$.




Fig. 3. Resveratrol decreases AP-1 activity in a *miR-663*-dependent manner. (A) AP-1 activity was measured in extracts of THP-1 cells transfected with the AP-1 luciferase reporter plasmid and with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h. Values represent the mean \pm standard deviation ($n = 3$). *, significantly different from the corresponding mock-challenged sample, $P < 0.005$. o and oo, significantly different from the corresponding vehicle-treated sample, o, $P < 0.03$, oo, $P < 0.001$. #, significantly different from the LPS-challenged resveratrol-treated Control, $P < 0.005$. ##, significantly different from the mock-challenged Vehicle-treated Control, $P < 0.0005$. (B) The effects of a 14 h resveratrol pretreatment on the accumulation of JunB following LPS challenge were determined by western blotting. (C) The levels of JunB in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I), treated with either vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h, were determined by western blotting. (D) Effects of a 14 h resveratrol treatment on the expression of wild-type (WT) or mutated (M663) *Luc-JunB* constructs in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I). Values represent the mean \pm standard deviation ($n = 4$). * and **, significantly different from the corresponding WT/Control, * P , 0.007 and ** P , 0.0009.




Fig. 4. Resveratrol opposes the upregulation of miR-155 at least in part by upregulating *miR-663*. (A) The relative expression of miR-155 in THP-1 cells transfected with either a Control RNA, pre-miR-663 (663) or a *miR-663* inhibitor RNA (663-I) and subsequently challenged or not with LPS for 6 h were determined by quantitative real-time PCR. Values represent the mean \pm standard deviation (n = 3). *, significantly different from the corresponding mockchallenged sample, $P < 0.06$. ^o, significantly different from LPS-challenged Control, $P < 0.005$. (B) Time-course of *miR-155* expression in LPS-challenged THP-1 cells preably treated with vehicle or resveratrol for 14 hours, as determined by quantitative real-time PCR. Values represent the mean \pm standard deviation (n = 3). (C) The levels of c-Maf in THP-1 cells pretreated with vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h were determined by western blotting. (D) The relative expression of *miR-155* in THP-1 cells transfected with either a Control RNA or a *miR-663* inhibitor RNA (663-I) and then pretreated with vehicle or resveratrol for 14 h and subsequently challenged or not with LPS for 6 h were determined by quantitative real-time PCR. Values represent the mean \pm standard deviation (n = 3). * and **, significantly different from the corresponding mock-challenged sample, * $P < 0.014$ and ** $P < 0.004$. ^o and ^{oo}, significantly different from LPS-challenged vehicle-treated Control, ^o $P < 0.02$ and ^{oo} $P < 0.0001$. #, significantly different from LPS-challenged resveratrol-treated Control, $P < 0.05$.